Navigation Links
Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
Date:2/27/2013

RICHMOND, Calif., Feb. 27, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Geoff Nichol , M.B., Ch.B., Sangamo's executive vice president, research and development, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 10:40 am ET on Wednesday, March 6, 2013, at the 33rd Annual Cowen and Company Health Care Conference which will be held in Boston.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
2. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
4. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
6. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
7. Neurocrine Biosciences Reports First Quarter 2012 Results
8. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
9. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
10. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
11. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2020)... , ... February 23, 2020 , ... ... the Next,” an examination of the complex interplay between the brain, central nervous ... the first time at the International Association of Eating Disorders Professionals (iaedp™) 2020 ...
(Date:2/21/2020)... Ala. (PRWEB) , ... February 21, 2020 , ... Nationwide ... Bipolar Disorder or Schizophrenia. While someone with a mental illness is no more likely ... crimes such as criminal trespass, loitering, or harassment. , They may be experiencing ...
(Date:2/21/2020)... ... February 21, 2020 , ... The business of healthcare management is complex. From ... trends and ensuring patients digital and physical safety, there are many things to keep ... why MaintenX International’s is excited to provide their insights on healthcare facility maintenance to ...
Breaking Medicine Technology:
(Date:2/23/2020)... ... February 22, 2020 , ... One of the ... https://www.imdb.com/name/nm0000401/mediaindex ) is the host of the informational program “Behind The Scenes.” “Behind ... people across the country. A soon to be aired episode will interview industry ...
(Date:2/21/2020)... Fla. (PRWEB) , ... February 21, 2020 , ... ... announced that it is now offering a 10 percent grand opening discount 0n ... 10 percent off all purchases," said Osmay Gonzalez, spokesperson for Baby Blendy LLC, ...
(Date:2/21/2020)... ... 2020 , ... Cosmetic surgery continues to grow in popularity ... (ASPS). According to the ASPS, there were 17.7-million cosmetic procedures performed in the ... The American Society of Plastic Surgeons reported that some of the most popular ...
(Date:2/20/2020)... ... , ... R3 Medical Training announced its next joint injection training courses scheduled ... injections for all large and small joints along with ultrasound needle guidance. , Performing ... opportunity is to perform injections in a supervised setting. R3 Medical Training's joint ...
(Date:2/20/2020)... ... February 20, 2020 , ... TMQuotes ... release with next generation API integration functionality which enables agents to take more ... in 2017, TMQuotes was the first white label software-as-a-service (SaaS) to give insurance ...
Breaking Medicine News(10 mins):